series-a
Stage
About
Aeromics is a clinical-stage pharmaceutical company developing AER-271, an intravenously administered aquaporin-4 inhibitor aimed at preventing and treating cerebral edema in patients suffering from severe acute ischemic stroke.
Explore Aeromics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.